NewAmsterdam Pharma Company N.V. (NAMS)
(Delayed Data from NSDQ)
$15.45 USD
-0.39 (-2.46%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $15.49 +0.04 (0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
NewAmsterdam Pharma Company N.V. (NAMS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$36.57 | $45.00 | $30.00 | 130.87% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for NewAmsterdam Pharma Company N.V. comes to $36.57. The forecasts range from a low of $30.00 to a high of $45.00. The average price target represents an increase of 130.87% from the last closing price of $15.84.
Analyst Price Targets (7 )
Broker Rating
NewAmsterdam Pharma Company N.V. currently has an average brokerage recommendation (ABR) of 1.22 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.13 a month ago based on eight recommendations.
Of the nine recommendations deriving the current ABR, seven are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 77.78% and 22.22% of all recommendations. A month ago, Strong Buy made up 87.5%, while Buy represented 12.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 2 | 2 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.22 | 1.22 | 1.13 | 1.13 | 1.13 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/28/2024 | Needham & Company | Serge Belanger | Not Available | Moderate Buy |
7/30/2024 | Scotiabank | George Farmer | Strong Buy | Strong Buy |
7/30/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/24/2024 | William Blair | Matt Phipps | Strong Buy | Strong Buy |
6/7/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/17/2024 | SVB Securities | Roanna Ruiz | Strong Buy | Strong Buy |
5/15/2024 | Cowen & Co. | Tyler Van Buren | Not Available | Strong Buy |
5/12/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
1/18/2024 | Guggenheim Securities | Debjit Chattopadhyay | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.22 |
ABR (Last week) | 1.22 |
# of Recs in ABR | 9 |
Average Target Price | $36.57 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 72 of 253 |
Current Quarter EPS Est: | -0.48 |
NAMS FAQs
NewAmsterdam Pharma Company N.V. (NAMS) currently has an average brokerage recommendation (ABR) of 1.22 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 9 brokerage firms.
The average price target for NewAmsterdam Pharma Company N.V. (NAMS) is $36.57. The current on short-term price targets is based on 4 reports.
The forecasts for NewAmsterdam Pharma Company N.V. (NAMS) range from a low of $30 to a high of $45. The average price target represents a increase of $136.70 from the last closing price of $15.45.
The current UPSIDE for NewAmsterdam Pharma Company N.V. (NAMS) is 136.70%
Based on short-term price targets offered by seven analysts, the average price target for NewAmsterdam Pharma Company N.V. comes to $36.57. The forecasts range from a low of $30.00 to a high of $45.00. The average price target represents an increase of 130.87% from the last closing price of $15.84.